In this discussion of ‘commercially reasonable efforts,’ Dr. Greg Bell explains how understanding the strategy behind a pharmaceutical product launch can inform development obligations in contract and licensing agreements. Click below to read the article.
CRA's RADAR Insights: Impact of US pricing strategies on orphan drug pricing in Germany - Part 3
In Part 3 of this series, RADAR data on orphan-drug pricing in Germany revealed a significant increase in manufacturer-set list prices for new orphan drugs...